surgical castration

PROCEDURE2 trials

Sponsors

National Cancer Institute, Egypt, National Cancer Institute Cairo University

Conditions

CancerProstate Cancer Metastatic

Phase 4

The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients

CompletedNCT04776889

National Cancer Institute, EgyptProstate Cancer Metastatic

Start: 2019-01-15End: 2020-12-30Updated: 2021-03-02

Unknown Phase

The Prognosis of Lipid Reprogramming with Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients

Active, not recruitingPACTR202102664354163

National Cancer Institute Cairo UniversityCancer

Start: 2019-01-01Target: 80Updated: 2026-09-14

Related Papers

The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial

PLoS ONE2022-12-087 citations